The controversy continues about the efficacy of PSA screening for prostate cancer. New recommendations were just issued from the USPSTF about who should be screened for prostate cancer and when. But not everyone agrees with these recommendations. Ballentine Carter, MD, from the Department of Urology at the Johns Hopkins School of Medicine, discusses the new recommendations and provides an expert urologist's perspective on PSA screening for prostate cancer. Related article
Fler avsnitt av JAMA Clinical Reviews
Visa alla avsnitt av JAMA Clinical ReviewsJAMA Clinical Reviews med JAMA Network finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
